As an adjunctive treatment, empagliflozin improves glycaemic control in patients with HNF1A-related maturity-onset diabetes ...

The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

A study led by the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

Recent developments of interest in cardiovascular medicine ...

Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages. Treatment with sodium-glucose ...

News, features, and commentary about cancer-related issues ...